Dudencer Special Precautions

When gastric ulcer is suspected, the possibility of malignancy should be excluded as treatment may alleviate symptoms and delay diagnosis.
Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with proton-pump inhibitors for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the proton-pump inhibitor. For patients expected to be on prolonged treatment or who take proton-pump inhibitor with medications such as digoxin or drugs that may cause hypomagnesemia (e.g. Diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of proton-pump inhibitor treatment and periodically.
Long-term (a year or longer) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. Patients should use lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
Subacute cutaneous lupus erythematosus (SCLE): Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Dudencer. SCLE after previous treatment with a proton-pump inhibitor may increase the risk of SCLE with other proton-pump inhibitors.
Use in Pregnancy & Lactation: As with all new drugs, Omeprazole should not be given during pregnancy and lactation unless its use is considered essential.